De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: A multicentre, open-label, randomized, controlled, non-inferiority trial
Nephrology Dialysis Transplantation Aug 12, 2017
Huh KH, et al. – The efficacy and safety of low–dose sirolimus (SRL) with extended–release tacrolimus (ER–TAC) versus mycophenolate mofetil (MMF) with ER–TAC were evaluated in this study. Regarding, efficacy and safety, low–dose SRL with ER–TAC was not inferior to MMF with ER–TAC. This study suggested the effectiveness of low–dose SRL with ER–TAC to prevent acute rejection and preserve renal function when used for immunosuppression in kidney transplantation.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
